Name: AT9283
Price: 260.00 USD

- Overview
  - Please contact us at for specific academic pricing.
    
    Background
    
    AT9283, a synthetic small heterocyclic molecule discovered using a fragment-based approach, is a novel inhibitor of aurora kinase, a family of serine/threonine kinases regulating both mitosis and meiosis, that potently inhibits Aurora kinases A and B, with 50% inhibition concentration IC50 value of 3 nM, as well as Janus kinases (JAKs), Abelson kinase (BCRABL T315I) and Flt-3. AT9283 has been found to be therapeutic in leukemic cells, myeloproliferative disorders and multiple solid tumor cell lines. Study results have shown that AT9283 exhibits anti-proliferative activity and induces polyploidy and apoptosis in aggressive B-cell NHL cell lines associated with inhibition of Aurora kinase B.
- Properties
  - Alternative Name
    
    1-cyclopropyl-3-[(3Z)-3-[5-(morpholin-4-ylmethyl)benzimidazol-2-ylidene]-1,2-dihydropyrazol-4-yl]urea
    
    CAS Number
    
    896466-04-9
    
    Molecular Formula
    
    C19H23N7O2
    
    Molecular Weight
    
    381.43
    
    Appearance
    
    A solid
    
    Purity
    
    98.00%
    
    Solubility
    
    insoluble in H2O; ≥19.05 mg/mL in DMSO; ≥47.6 mg/mL in EtOH with ultrasonic
    
    Storage
    
    Store at -20°C
    
    * For Research Use Only
- Reference
  - 1. Laura Torrente, Gunjit Maan, et al. "High NRF2 Levels Correlate with Poor Prognosis in Colorectal Cancer Patients and with Sensitivity to the Kinase Inhibitor AT9283 In Vitro." Biomolecules. 2020 Sep 25;10(10):1365. PMID:32992842
    2. Laura Torrente, Gunjit Maan, et al. "The kinase inhibitor AT9283 selectively kills colorectal cancer cells with hyperactive NRF2." bioRxiv. 2019, October 21.

AT9283

AT9283

Background

We Also Recommend

AMG-900

Hesperadin

MK-5108 (VX-689)